Verastem Oncology Cancer Drug Combination Gets FDA Approval

Published: 2025-05-08 13:55:07 ET VSTM

Published on 05/08/2025 at 13:55

By Josh Beckerman

Verastem Oncology said the Food and Drug Administration approved the combination of avutometinib capsules and defactinib tablets for certain patients with KRAS-mutated recurrent low-grade serous ovarian cancer.

The company expects a combination co-pack will be available in the U.S. in about a week.

The approval was in advance of the June 30 Prescription Drug User Fee Act action date.

Verastem shares were flat at $6.69 prior to a trading halt for pending news.

Write to Josh Beckerman at [email protected]

(END) Dow Jones Newswires

05-08-25 1354ET